BCR-ABL-IN-3

Modify Date: 2024-01-02 18:24:19

BCR-ABL-IN-3 structure	Common Name	BCR-ABL-IN-3
	CAS Number	2240191-12-0	Molecular Weight	466.89
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₀H₁₇ClF₂N₄O₃S	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of BCR-ABL-IN-3

BCR-ABL-IN-3 is a potent and irreversible Bcr-Abl inhibitor with an IC50 of ≤100 nM for Ba/F3Bcr-AblT3151. BCR-ABL-IN-3 has anti-cancer activity[1].

Name	BCR-ABL-IN-3

Description	BCR-ABL-IN-3 is a potent and irreversible Bcr-Abl inhibitor with an IC50 of ≤100 nM for Ba/F3Bcr-AblT3151. BCR-ABL-IN-3 has anti-cancer activity[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Bcr-Abl
Target	Ba/F3Bcr-AblT3151:≤100 nM (IC50)
In Vivo	BCR-ABL-IN-3 (compound 7; 15 mg/kg; twice a day; for 19 days) has good antitumor effect in female NOD/SCID mice of 7-8 weeks weighing 21.8 g with Ba/F3Bcr-AblT3151 cells[1]. BCR-ABL-IN-3 (2 mg/kg for IV or 20mg/kg for PO) has a Cmax of 5485 ng/mL and an AUC of 5450 h•ng/mL for IV in male Sprague Dawley rats of 7-8 weeks old weighing 210 g[1].
References	[1]. Hanyi Wang, et al. (hetero)arylamide compound for inhibiting protein kinase activity. WO2018133826A1.

Molecular Formula	C₂₀H₁₇ClF₂N₄O₃S
Molecular Weight	466.89